The Roche group was able to grow net income faster than sales in 2016 on the back of a series of new pharmaceutical product launches that included Tecentriq (atezolizumab), its first cancer immunotherapy. Tecentriq is a PD-L1 inhibitor for both bladder and lung cancer.
